Literature DB >> 11414762

Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.

L Argiro1, M Desbarats, F H Glorieux, B Ecarot.   

Abstract

The MEPE (matrix extracellular phosphoglycoprotein) gene is a strong candidate for the tumor-derived phosphaturic factor in oncogenic hypophosphatemic osteomalacia (OHO). X-linked hypophosphatemia (XLH) is phenotypically similar to OHO and results from mutations in PHEX, a putative metallopeptidase believed to process a factor(s) regulating bone mineralization and renal phosphate reabsorption. Here we report the isolation of the murine homologue of MEPE, from a bone cDNA library, that encodes a protein of 433 amino acids, 92 amino acids shorter than human MEPE. Mepe, like Phex, is expressed by fully differentiated osteoblasts and down-regulated by 1,25-(OH)2D3. In contrast to Phex, Mepe expression is markedly increased during osteoblast-mediated matrix mineralization. Greater than normal Mepe mRNA levels were observed in bone and osteoblasts derived from Hyp mice, the murine homologue of human XLH. Our data provide the first evidence that MEPE/Mepe is expressed by osteoblasts in association with mineralization. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414762     DOI: 10.1006/geno.2001.6553

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  46 in total

1.  Mepe is expressed during skeletal development and regeneration.

Authors:  Chuanyong Lu; Steve Huang; Theodore Miclau; Jill A Helms; Céline Colnot
Journal:  Histochem Cell Biol       Date:  2004-05-15       Impact factor: 4.304

2.  MEPE expression in osteocytes during orthodontic tooth movement.

Authors:  J Gluhak-Heinrich; D Pavlin; W Yang; M MacDougall; S E Harris
Journal:  Arch Oral Biol       Date:  2007-01-31       Impact factor: 2.633

3.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

4.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

5.  Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.

Authors:  Yasuo Imanishi; Jun Hashimoto; Wataru Ando; Keisuke Kobayashi; Takafumi Ueda; Yuki Nagata; Akimitsu Miyauchi; Hajime M Koyano; Hiroshi Kaji; Takatoshi Saito; Koichi Oba; Yasato Komatsu; Tomoaki Morioka; Katsuhito Mori; Takami Miki; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2011-07-08       Impact factor: 2.626

6.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

7.  Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.

Authors:  Guoying Liang; Lee D Katz; Karl L Insogna; Thomas O Carpenter; Carolyn M Macica
Journal:  Calcif Tissue Int       Date:  2009-07-17       Impact factor: 4.333

8.  Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.

Authors:  Gui Xia Zhang; Morimichi Mizuno; Kiyomi Tsuji; Masato Tamura
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

9.  MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers.

Authors:  P Zhang; H Wang; P S N Rowe; B Hu; Y Wang
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

10.  MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1.

Authors:  Shuang Liu; Hongyan Wang; Xiang Wang; Lin Lu; Ning Gao; Peter S N Rowe; Baocheng Hu; Ya Wang
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.